PYXS News and Press, Pyxis Oncology Inc. From 03/29/22

Pyxis Oncology press release (NASDAQ:PYXS): FY GAAP EPS of -$8.95 misses by $5.88. As of March 29, 2022, cash and cash equivalents of approximately $253M For further details see: Pyxis Oncology GAAP EPS of -$8.95 misses by $5.88

Announces Expansion of Novel Immuno-Oncology Therapeutic Portfolio with Addition of Anti-Siglec-15 In-licensed from Biosion (PYX-106) Introduces First Internally Developed IO Candidate Anti-KLRG1 (PYX-102) Cash Runway Sufficient for Multiple Milestones Through Third Quar...

CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset, multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced it will host a conference call and live webcast on Tuesday, Marc...

Gainers: Revelation Biosciences REVB +29%. Mainz Biomed MYNZ +9%. Relmada Therapeutics (NASDAQ:RLMD) +9%. Panbela Therapeutics (NASDAQ:PBLA) +7%. Pyxis Oncology (NASDAQ:PYXS) +4%. Losers: Kodiak Sciences KOD -78%. Ocugen OCGN -20%. R...

CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that the company will be added to the Russell 2000® Index, effectiv...

CAMBRIDGE, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced the appointment of Martina Molsbergen as Interim Chief Business Officer. Ms. Molsbergen will be responsible for managing the Company’s current partnerships and joint ventures as we...

Pyxis Oncology (NASDAQ:PYXS) tumbled more than 20% Monday to a post-IPO low as the cancer-drug developer’s stock apparently sank on a key executive’s departure. PYXS fell as much as 25.5% to $9.08 before partly recovering to end the day at a $9.64 record-low finish, off 20.9% fo...

Pyxis Oncology (NASDAQ:PYXS): Q3 GAAP EPS of -$8.96. Pyxis has a strong cash position of ~$283M as of November 15, 2021 which is expected to fund operations into the second half of 2024. Press Release For further details see: Pyxis Oncology reports Q3 results

CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its third quarter ended September 30, 2021 and prov...

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), today announced that management will present at and host one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021. Th...